This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PEG-Infergen

Roche Holding AG

Drug Names(s): PEG-interferon alfacon-1

Description: PEG-Infergen is a pegylated form of Interferon-alfacon-1 (Infergen). Infergen is marketed for the treatment of adults with chronic hepatitis C virus infections. The pegylated version may offer advantages of a less frequent dosing schedule and enhanced anti-viral effect by maintaining therapeutic concentrations in the body for a longer period of time.

Deal Structure: InterMune is using Nektar's Advanced PEGylation technology to develop PEG-Alfacon, a PEGylated version of Infergen.

Partners: Nektar Therapeutics


PEG-Infergen News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug